JP2019518046A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019518046A5 JP2019518046A5 JP2018565675A JP2018565675A JP2019518046A5 JP 2019518046 A5 JP2019518046 A5 JP 2019518046A5 JP 2018565675 A JP2018565675 A JP 2018565675A JP 2018565675 A JP2018565675 A JP 2018565675A JP 2019518046 A5 JP2019518046 A5 JP 2019518046A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- ring
- alkyl
- aromatic
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 58
- 125000000217 alkyl group Chemical group 0.000 claims description 36
- 125000001424 substituent group Chemical group 0.000 claims description 21
- 125000003118 aryl group Chemical group 0.000 claims description 13
- 125000005843 halogen group Chemical group 0.000 claims description 13
- 229910052739 hydrogen Inorganic materials 0.000 claims description 12
- 239000001257 hydrogen Substances 0.000 claims description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 12
- 125000001153 fluoro group Chemical group F* 0.000 claims description 11
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- 201000008827 tuberculosis Diseases 0.000 claims description 6
- 125000004429 atoms Chemical group 0.000 claims description 5
- 125000005842 heteroatoms Chemical group 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 125000004433 nitrogen atoms Chemical group N* 0.000 claims description 4
- 206010060945 Bacterial infection Diseases 0.000 claims description 3
- 229940072185 DRUGS FOR TREATMENT OF TUBERCULOSIS Drugs 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 125000005647 linker group Chemical group 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 125000005418 aryl aryl group Chemical group 0.000 claims description 2
- 125000002619 bicyclic group Chemical group 0.000 claims description 2
- 230000001808 coupling Effects 0.000 claims description 2
- 238000010168 coupling process Methods 0.000 claims description 2
- 238000005859 coupling reaction Methods 0.000 claims description 2
- 125000004122 cyclic group Chemical group 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000001072 heteroaryl group Chemical group 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 239000001301 oxygen Chemical group 0.000 claims description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical group O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
- 229910052717 sulfur Chemical group 0.000 claims description 2
- 239000011593 sulfur Chemical group 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 claims 2
- 230000002365 anti-tubercular Effects 0.000 claims 1
- 229940079593 drugs Drugs 0.000 claims 1
- -1 eg fluoro atoms) Chemical group 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 150000002829 nitrogen Chemical group 0.000 description 4
- 125000001140 1,4-phenylene group Chemical group [H]C1=C([H])C([*:2])=C([H])C([H])=C1[*:1] 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atoms Chemical group C* 0.000 description 1
- 239000000814 tuberculostatic agent Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16174719 | 2016-06-16 | ||
| EP16174719.1 | 2016-06-16 | ||
| PCT/EP2017/064652 WO2017216281A1 (en) | 2016-06-16 | 2017-06-15 | Heterocyclic compounds as antibacterials |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019518046A JP2019518046A (ja) | 2019-06-27 |
| JP2019518046A5 true JP2019518046A5 (pt-PT) | 2020-08-13 |
Family
ID=56132837
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018565675A Pending JP2019518046A (ja) | 2016-06-16 | 2017-06-15 | 抗菌薬としての複素環式化合物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11179396B2 (pt-PT) |
| EP (1) | EP3472158A1 (pt-PT) |
| JP (1) | JP2019518046A (pt-PT) |
| KR (1) | KR20190017948A (pt-PT) |
| CN (1) | CN109476657A (pt-PT) |
| AU (1) | AU2017286368B2 (pt-PT) |
| BR (1) | BR112018076126A2 (pt-PT) |
| CA (1) | CA3026010A1 (pt-PT) |
| EA (1) | EA201990043A1 (pt-PT) |
| MA (1) | MA45377A (pt-PT) |
| MX (1) | MX2018015656A (pt-PT) |
| WO (1) | WO2017216281A1 (pt-PT) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4074378A1 (en) | 2015-07-02 | 2022-10-19 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| PE20181352A1 (es) | 2015-09-17 | 2018-08-22 | Marvin J Miller | Compuestos heterociclicos que contienen bencilamina y composiciones utiles contra infeccion por micobacterias |
| CN109476657A (zh) | 2016-06-16 | 2019-03-15 | 爱尔兰詹森科学公司 | 作为抗细菌剂的杂环化合物 |
| BR112019017901A2 (pt) | 2017-03-01 | 2020-05-12 | Janssen Sciences Ireland Unlimited Company | Terapia de combinação |
| EP3684767B1 (en) | 2017-09-22 | 2024-04-24 | Jubilant Epipad LLC | Heterocyclic compounds as pad inhibitors |
| KR20200071752A (ko) | 2017-10-18 | 2020-06-19 | 주빌런트 에피파드 엘엘씨 | Pad 억제제로서의 이미다조-피리딘 화합물 |
| US11629135B2 (en) | 2017-11-06 | 2023-04-18 | Jubilant Prodell Llc | Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation |
| SG11202004537UA (en) | 2017-11-24 | 2020-06-29 | Jubilant Episcribe Llc | Heterocyclic compounds as prmt5 inhibitors |
| JP7279063B6 (ja) | 2018-03-13 | 2024-02-15 | ジュビラント プローデル エルエルシー | Ｐｄ１／ｐｄ－ｌ１相互作用／活性化の阻害剤としての二環式化合物 |
| TW202124379A (zh) | 2019-09-10 | 2021-07-01 | 日商鹽野義製藥股份有限公司 | 對分枝桿菌感染有用之含苄胺的５，６－雜芳族化合物 |
| WO2021048342A1 (en) | 2019-09-13 | 2021-03-18 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| CA3151288A1 (en) * | 2019-09-26 | 2021-04-01 | Takushi Kaneko | Thiazole carboxamide compounds and use thereof for the treatment of mycobacterial infections |
| BR112022005068A2 (pt) | 2019-09-30 | 2022-09-06 | Janssen Sciences Ireland Unlimited Co | Compostos antibacterianos de 4-quinolinona |
| MX2022003816A (es) | 2019-09-30 | 2022-05-06 | Janssen Sciences Ireland Unlimited Co | Compuestos antibacterianos. |
| CA3211532A1 (en) | 2021-03-16 | 2022-09-22 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| BR112023018654A2 (pt) | 2021-03-17 | 2023-10-03 | Janssen Sciences Ireland Unlimited Co | Compostos antibacterianos |
| BR112023018655A2 (pt) | 2021-03-17 | 2023-12-12 | Janssen Sciences Ireland Unlimited Co | Compostos antibacterianos |
| WO2022214519A1 (en) | 2021-04-07 | 2022-10-13 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| WO2022214520A1 (en) | 2021-04-07 | 2022-10-13 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| AU2022377203A1 (en) | 2021-10-28 | 2024-06-13 | Janssen Sciences Ireland Unlimited Company | Imidazopyridine amides and related compounds for use in the treatment of bacterial infections |
| WO2024089170A1 (en) | 2022-10-27 | 2024-05-02 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5952324A (en) | 1994-11-15 | 1999-09-14 | Pharmacia & Upjohn Company | Bicyclic oxazine and thiazine oxazolidinone antibacterials |
| DK0828741T3 (da) * | 1995-05-11 | 2001-11-26 | Upjohn Co | Spirocykliske og bicykliske diazinyl- og carbazinyloxazolidinoner |
| PT2301544E (pt) | 2002-07-25 | 2012-12-10 | Janssen Pharmaceutica Nv | Novos inibidores de micobactérias |
| AR042956A1 (es) | 2003-01-31 | 2005-07-13 | Vertex Pharma | Inhibidores de girasa y usos de los mismos |
| MA27360A1 (fr) | 2004-11-23 | 2005-06-01 | Brahim Bennani | Synthese et application des spiro-isoxazolines comme agents anti-tuberculeux |
| JP2010513495A (ja) | 2006-12-20 | 2010-04-30 | シェーリング コーポレイション | 新規なｊｎｋ阻害剤 |
| TW200901969A (en) | 2007-06-06 | 2009-01-16 | Smithkline Beecham Corp | Chemical compounds |
| TWI498115B (zh) | 2007-12-27 | 2015-09-01 | Daiichi Sankyo Co Ltd | 咪唑羰基化合物 |
| AU2009228293B2 (en) | 2008-03-26 | 2012-11-08 | Tennor Therapeutics (Suzhou) Limited | Bicyclic nitroimidazoles covalently linked to substituted phenyl oxazolidinones |
| EP2385371B1 (en) | 2008-09-22 | 2014-10-22 | Oregon Health and Science University | Methods for detecting a mycobacterium tuberculosis infection |
| WO2010078408A1 (en) | 2008-12-30 | 2010-07-08 | Biogen Idec Ma Inc. | Heteroaryl compounds useful as raf kinase inhibitors |
| CN110483499A (zh) | 2009-11-05 | 2019-11-22 | 圣母大学 | 咪唑并[1,2-a]吡啶类化合物及其合成及使用方法 |
| SG10201502109VA (en) * | 2010-03-18 | 2015-05-28 | Pasteur Institut Korea | Anti-infective compounds |
| KR102104125B1 (ko) | 2011-04-21 | 2020-05-29 | 재단법인 한국파스퇴르연구소 | 소염 화합물 |
| US9199981B2 (en) | 2011-09-01 | 2015-12-01 | Novartis Ag | Compounds and compositions as C-kit kinase inhibitors |
| PT2751104T (pt) | 2011-09-01 | 2019-12-16 | Novartis Ag | Compostos e composições como inibidores de c-kit quinase |
| CN104520290B (zh) | 2012-03-02 | 2020-10-09 | 基因科技股份有限公司 | 酰氨基螺环酰胺和磺酰胺衍生物 |
| KR101918469B1 (ko) | 2012-06-04 | 2018-11-15 | 한국화학연구원 | 바이사이클릭 니트로이미다졸 유도체 또는 이들의 광학이성질체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 약제학적 조성물 |
| BR112015001201B1 (pt) | 2012-07-18 | 2022-02-22 | University Of Notre Dame Du Lac | Compostos anti-infecciosos 5,5-heteroaromáticos e composição |
| EA201590339A1 (ru) * | 2012-08-10 | 2015-06-30 | Янссен Сайенсиз Айрлэнд Юси | Новые антибактериальные соединения |
| KR101650716B1 (ko) | 2012-11-22 | 2016-08-24 | 한국화학연구원 | 바이시클릭니트로이미다졸 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 결핵의 예방 또는 치료용 약학적 조성물 |
| HUE056198T2 (hu) | 2013-08-02 | 2022-02-28 | Pasteur Institut Korea | Fertõzés elleni vegyületek |
| KR101564425B1 (ko) | 2013-11-26 | 2015-10-30 | 한국화학연구원 | 신규한 바이사이클릭 니트로이미다졸 카바메이트 화합물, 이를 제조하는 방법 및 이를 유효성분으로 함유하는 결핵 질환의 예방 또는 치료용 약제학적 조성물 |
| CN105524058B (zh) * | 2014-10-21 | 2018-03-27 | 广州艾格生物科技有限公司 | 吡唑并[1,5‑a]吡啶类化合物及其应用 |
| WO2016073524A1 (en) | 2014-11-03 | 2016-05-12 | The Regents Of The University Of California | Multi-drug therapies for tuberculosis treatment |
| EP4074378A1 (en) | 2015-07-02 | 2022-10-19 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| CN109476657A (zh) | 2016-06-16 | 2019-03-15 | 爱尔兰詹森科学公司 | 作为抗细菌剂的杂环化合物 |
| AU2017286370B2 (en) | 2016-06-16 | 2021-09-09 | Janssen Sciences Ireland Uc | Heterocyclic compounds as antibacte rials |
| BR112019017901A2 (pt) | 2017-03-01 | 2020-05-12 | Janssen Sciences Ireland Unlimited Company | Terapia de combinação |
-
2017
- 2017-06-15 CN CN201780037229.4A patent/CN109476657A/zh active Pending
- 2017-06-15 MX MX2018015656A patent/MX2018015656A/es unknown
- 2017-06-15 EP EP17729877.5A patent/EP3472158A1/en not_active Withdrawn
- 2017-06-15 MA MA045377A patent/MA45377A/fr unknown
- 2017-06-15 BR BR112018076126-5A patent/BR112018076126A2/pt not_active Application Discontinuation
- 2017-06-15 JP JP2018565675A patent/JP2019518046A/ja active Pending
- 2017-06-15 CA CA3026010A patent/CA3026010A1/en not_active Abandoned
- 2017-06-15 AU AU2017286368A patent/AU2017286368B2/en not_active Ceased
- 2017-06-15 US US16/309,725 patent/US11179396B2/en active Active
- 2017-06-15 WO PCT/EP2017/064652 patent/WO2017216281A1/en unknown
- 2017-06-15 EA EA201990043A patent/EA201990043A1/ru unknown
- 2017-06-15 KR KR1020197000960A patent/KR20190017948A/ko not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019518046A5 (pt-PT) | ||
| JP2019518050A5 (pt-PT) | ||
| JP2018519302A5 (pt-PT) | ||
| JP2018524339A5 (pt-PT) | ||
| RU2403258C2 (ru) | Тиазолилдигидроиндазолы | |
| JP2017524025A5 (pt-PT) | ||
| JP2017527532A5 (pt-PT) | ||
| CR20210627A (es) | Derivados de benzisoxazol sulfonimada | |
| JP2013532652A5 (pt-PT) | ||
| JP2019529444A5 (pt-PT) | ||
| JP2014500295A5 (pt-PT) | ||
| JP2020097577A5 (pt-PT) | ||
| PT76336A (de) | Cephalosporinderivate und verfahren zu ihrer herstellung | |
| CA2656716C (fr) | Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique | |
| JP2019526596A5 (pt-PT) | ||
| JP2017510610A5 (pt-PT) | ||
| MX2010007374A (es) | Nuevos derivados de c-21-ceto lupano, preparacion y uso de los mismos. | |
| RU2007125130A (ru) | Применение атазанавира для улучшения фармакокинетики лекарственных средств, метаболизируемых ugt1a1 | |
| JP2013542267A5 (pt-PT) | ||
| JP2019527724A5 (pt-PT) | ||
| JP2015522592A5 (pt-PT) | ||
| UA81640C2 (ru) | Противомикобактериальные соединения, способ их получения, фармацевтическая композиция на их основе | |
| KR940702491A (ko) | 옥사졸리돈 유도체 | |
| JPWO2021030556A5 (pt-PT) | ||
| CA3155875A1 (en) | BIARYL COMPOUND SUBSTITUTED BY SULFO OR CORRESPONDING SALT, METHOD FOR PREPARATION AND USE |